Глобальная стратегия лечения бронхиальной астмы - часть 14

3.     Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting

with the CFC

4.     Harrison LI, Soria I, Cline AC, Ekholm BP. Pharmacokinetic 

differences between chlorofluorocarbon and chlorofluorocar

5.     Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ,

Fireman P. Clinically important improvements in asthma

6.     Langley PC. The technology of metered

ment costs in asthma: a retrospective study of breath actuation
versus traditional press

7.     Newman SP. A comparison of lung deposition patterns between

different asthma inhalers. J Aerosol Med 1995;8 Suppl 3:21

8.     Newman SP. Inhaler treatment options in COPD. Eur Respir Rev

2005;14(96):102

9.     Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, 

O’Byrne PM, Hargreave FE. Effect of long

10.   Long

asthma. The Childhood Asthma Management Program Research
Group. N Engl J Med 2000;343(15):1054

11.   Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A,

Johansson SA. Effects of treatment on airway inflammation and
thickening of basement membrane reticular collagen in asthma.
A quantitative light and electron microscopic study. Am Rev
Respir Dis 1992;145(4 Pt 1):890

12.   Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P,

Barnes PJ, et al. Effect of inhaled formoterol and budesonide on
exacerbations of asthma. Formoterol and Corticosteroids
Establishing Therapy (FACET) International Study Group. N Engl
J Med 1997;337(20):1405

13.   Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low

inhaled corticosteroids and the prevention of death from asth

14.   Waalkens HJ, Van Essen

Duiverman EJ, Knol K, et al. Cessation of long

15.   Jayasiri B, Perera C. Successful withdrawal of inhaled cortico

steroids in childhood asthma. Respirology 2005;10:385

16.   National Asthma Education and Prevention Program. Guidelines

for the diagnosis and management of asthma. Bethesda, MD:
National Heart, Lung, and Blood Institute. National Institutes of
Health; 1997.

17.   Powell H, Gibson PG. Inhaled corticosteroid doses 

in asthma: an evidence

18.   Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM,

Chinchilli VM, et al. Significant variability in response to inhaled
corticosteroids for persistent asthma. J Allergy Clin Immunol
2002;109(3):410

19.   Lipworth BJ, Kaliner MA, LaForce CF, Baker JW, Kaiser HB, 

Amin D, et al. Effect of ciclesonide and fluticasone on hypothala

ate persistent asthma. Ann Allergy Asthma Immunol
2005;94(4):465

20.   Lipworth BJ. Systemic adverse effects of inhaled corticosteroid

therapy: A systematic review and meta

21.   Barnes PJ. Efficacy of inhaled corticosteroids in asthma. 

J Allergy Clin Immunol 1998;102(4 Pt 1):531

22.   Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM,

Drazen JM, et al. Issues in the use of inhaled glucocorticoids.
The Asthma Clinical Research Network. Am J Respir Crit Care
Med 1996;153(6 Pt 1):1739

23.   Lee DK, Bates CE, Currie GP, Cowan LM, McFarlane LC,

Lipworth BJ. Effects of high

24.   Mak VH, Melchor R, Spiro SG. Easy bruising as a side

inhaled corticosteroids. Eur Respir J 1992;5(9):1068

25.   Effect of inhaled triamcinolone on the decline in pulmonary

function in chronic obstructive pulmonary disease. N Engl J Med
2000;343(26):1902

26.   Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and

efficacy of fluticasone and beclomethasone in moderate to
severe asthma. Belgian Multicenter Study Group. Am J Respir
Crit Care Med 1998;157(3 Pt 1):827

27.   Ernst P, Baltzan M, Deschenes J, Suissa S. Low

and nasal corticosteroid use and the risk of cataracts. 
Eur Respir J 2006;27(6):1168

28.   Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glu

cocorticoids and the risks of ocular hypertension or openangle
glaucoma. JAMA 1997;277(9):722

29.   Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticoste

roids and the risk of cataracts. N Engl J Med 1997;337(1):8

30.   Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular

cataracts, bruises and hoarseness in children with asthma
receiving long

31.   Toogood JH, Markov AE, Baskerville J, Dyson C. Association of

ocular cataracts with inhaled and oral steroid therapy during
long

32.   Simons FE, Persaud MP, Gillespie CA, Cheang M, Shuckett EP.

Absence of posterior subcapsular cataracts in young patients
treated with inhaled glucocorticoids. Lancet
1993;342(8874):776

33.   Bahceciler NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB,

Basaran MM. Inhaled corticosteroid therapy is safe in tuber

34.   Dicpinigaitis PV, Dobkin JB, Reichel J. Antitussive effect of the

leukotriene receptor antagonist zafirlukast in subjects with
cough

35.   Lipworth BJ. Leukotriene

1999;353(9146):57

36.   Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with

drugs modifying the leukotriene pathway. N Engl J Med
1999;340(3):197

37.   Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist

therapy on the risk of asthma exacerbations in patients with mild
to moderate asthma: an integrated analysis of zafirlukast trials.
Thorax 2000;55(6):478

38.   Noonan MJ, Chervinsky P, Brandon M, Zhang J, Kundu S,

McBurney J, et al. Montelukast, a potent leukotriene receptor
antagonist, causes dose

60 ЛЕКАРСТВЕННЫЕ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ

ma. Montelukast Asthma Study Group. Eur Respir J
1998;11(6):1232

39.   Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B,

Edwards TB. Montelukast, a once

40.   Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, 

Hendeles L, et al. Montelukast, a leukotriene

41.   Dahlen B, Nizankowska E, Szczeklik A, Zetterstrom O, Bochenek G,

Kumlin M, et al. Benefits from adding the 5

42.   Bleecker ER, Welch MJ, Weinstein SF, Kalberg C, Johnson M,

Edwards L, et al. Low

43.   Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, 

Peszek I, et al. Montelukast added to inhaled beclomethasone in
treatment of asthma. Montelukast/Beclomethasone Additivity
Group. Am J Respir Crit Care Med 1999;160(6):1862

44.   Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al.

Randomised, placebo controlled trial of effect of a leukotriene
receptor antagonist, montelukast, on tapering inhaled cortico

45.   Virchow JC, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast

improves asthma control in patients receiving high

46.   Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, 

James IG, et al. Randomised controlled trial of montelukast plus
inhaled budesonide versus double dose inhaled budesonide in
adult patients with asthma. Thorax 2003;58(3):211

47.   Vaquerizo MJ, Casan P, Castillo J, Perpina M, Sanchis J,

Sobradillo V, et al. Effect of montelukast added to inhaled budes

48.   Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP,

Haahtela T, et al. Montelukast and fluticasone compared with sal

49.   Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K,

et al. Fluticasone propionate/salmeterol combination provides
more effective asthma control than low

50.   Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, et al.

Salmeterol powder provides significantly better benefit than mon

51.   Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M,

et al. The salmeterol/fluticasone combination is more effective
than fluticasone plus oral montelukast in asthma. Respir Med
2003;97(3):234

52.   Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A,

Haranath SP, et al. Churg

53.   Wechsler ME, Pauwels R, Drazen JM. Leukotriene modifiers and

Churg

54.   Harrold LR, Andrade SE, Go AS, Buist AS, Eisner M, Vollmer WM,

et al. Incidence of Churg

55.   Lemanske RF, Jr., Sorkness CA, Mauger EA, Lazarus SC, 

Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and
elimination in patients with persistent asthma receiving salmeterol:
a randomized controlled trial. JAMA 2001;285(20):2594

56.   Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr.,

Sorkness CA, et al. Long

57.   Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL,

Kemp JP, et al. A comparison of salmeterol with albuterol in the
treatment of mild

58.   Kesten S, Chapman KR, Broder I, Cartier A, Hyland RH, Knight A,

et al. A three

59.   Wenzel SE, Lumry W, Manning M, Kalberg C, Cox F, Emmett A, 

et al. Efficacy, safety, and effects on quality of life of salmeterol
versus albuterol in patients with mild to moderate persistent asth

60.   Shrewsbury S, Pyke S, Britton M. Meta

of inhaled steroid or addition of salmeterol in symptomatic asthma
(MIASMA). BMJ 2000;320(7246):1368

61.   Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of

addition of salmeterol to inhaled steroids with doubling of the
dose of inhaled steroids. Am J Respir Crit Care Med
1996;153(5):1481

62.   Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol ver

sus higher

63.   Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ,

Pauwels RA, et al. Can guideline

64.   Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, 

Johansen B, et al. Budesonide and formoterol in a single inhaler
improves asthma control compared with increasing the dose of
corticosteroid in adults with mild

65.   Kips JC, O’Connor BJ, Inman MD, Svensson K, Pauwels RA,

O’Byrne PM. A long

66.   Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza

Rosenzweig JR. Improved refill persistence with fluticasone propi

67.   Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, 

Atienza T, et al. Budesonide/formoterol in a single inhaler for
maintenance and relief in mild

68.   O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M,

Zhu Y, et al. Budesonide/formoterol combination therapy as both
maintenance and reliever medication in asthma. Am J Respir Crit
Care Med 2005;171(2):129

69.   Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L,

Centanni S, et al. Efficacy and safety of budesonide/formoterol
single inhaler therapy versus a higher dose of budesonide in
moderate to severe asthma. Curr Med Res Opin
2004;20(9):1403

70.   Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M, 

Boutet S, et al. Budesonide/formoterol maintenance and reliever

ЛЕКАРСТВЕННЫЕ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ  61

therapy: an effective asthma treatment option? Eur Respir J
2005;26(5):819

71.   Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, 

McFadden ER, Jr. Effect of long

72.   Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, 

Lotvall J. Inhaled dry

73.   van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, 

Maesen FP. Salmeterol versus formoterol in patients with moder

74.   Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsen

sitivity after chronic dosing with eformoterol in patients with asth

75.   Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. 

The Salmeterol Multicenter Asthma Research Trial: a comparison
of usual pharmacotherapy for asthma or usual pharmacotherapy
plus salmeterol. Chest 2006;129(1):15

76.   Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, 

Craig TJ, et al. Use of regularly scheduled albuterol treatment 
in asthma: genotype

77.   Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti

inflammatory effects of low

78.   Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, 

Barnes PJ. Immunomodulation by theophylline in asthma.
Demonstration by withdrawal of therapy. Am J Respir Crit Care
Med 1995;151(6):1907

79.   Barnes PJ. Theophylline: new perspectives for an old drug. Am J

Respir Crit Care Med 2003;167(6):813

80.   Dahl R, Larsen BB, Venge P. Effect of long

inhaled budesonide or theophylline on lung function, airway reac

81.   Rivington RN, Boulet LP, Cote J, Kreisman H, Small DI, 

Alexander M, et al. Efficacy of Uniphyl, salbutamol, and their com

82.   Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Connor BJ,

Barnes PJ. A comparison of low

83.   Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, 

Steffen H, et al. Comparison of addition of theophylline to
inhaled steroid with doubling of the dose of inhaled steroid in
asthma. Eur Respir J 1997;10(12):2754

84.   Baba K, Sakakibara A, Yagi T, Niwa S, Hattori T, Koishikawa I, 

et al. Effects of theophylline withdrawal in well

85.   Davies B, Brooks G, Devoy M. The efficacy and safety of salme

terol compared to theophylline: meta

86.   Wilson AJ, Gibson PG, Coughlan J. Long acting beta

versus theophylline for maintenance treatment of asthma.
Cochrane Database Syst Rev 2000;2.

87.   Ahn HC, Lee YC. The clearance of theophylline is increased dur

ing the initial period of tuberculosis treatment. Int J Tuberc Lung
Dis 2003;7(6):587

88.   Szefler SJ, Nelson HS. Alternative agents for anti

treatment of asthma. J Allergy Clin Immunol 1998;102 (4 Pt 2):
S23

89.   Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J,

et al. Benefits of omalizumab as add

90.   Milgrom H, Fick RB, Jr., Su JQ, Reimann JD, Bush RK, 

Watrous ML, et al. Treatment of allergic asthma with monoclonal
anti

91.   Busse W, Corren J, Lanier BQ, McAlary M, Fowler

Cioppa GD, et al. Omalizumab, anti

92.   Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H.

Predicting response to omalizumab, an anti

93.   Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB,

Chung KF, et al. Efficacy and safety of a recombinant anti

94.   Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, 

Chung KF, et al. Effects of treatment with anti

95.   Mash B, Bheekie A, Jones PW. Inhaled vs oral steroids for adults

with chronic asthma. Cochrane Database Syst Rev 2000;2.

96.   Toogood JH, Baskerville J, Jennings B, Lefcoe NM, 

Johansson SA. Bioequivalent doses of budesonide and pred

97.   Recommendations for the prevention and treatment of gluco

corticoid

98.   Campbell IA, Douglas JG, Francis RM, Prescott RJ, Reid DM.

Five year study of etidronate and/or calcium as prevention and
treatment for osteoporosis and fractures in patients with asthma
receiving long term oral and/or inhaled glucocorticoids. Thorax
2004;59(9):761

99.   Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM,

et al. A UK Consensus Group on management of glucocorticoid

100. Guillevin L, Pagnoux C, Mouthon L. Churg

Semin Respir Crit Care Med 2004;25(5):535

101. Kurosawa M. Anti

the clinical outcome. Clin Exp Allergy 1994;24(4):299

102. Aaron SD, Dales RE, Pham B. Management of steroiddependent

asthma with methotrexate: a meta

103. Marin MG. Low

steroid

104. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing

agent for asthma in adults. Cochrane Database Syst Rev 2000;2.

105. Lock SH, Kay AB, Barnes NC. Double

study of cyclosporin A as a corticosteroid

106. Bernstein IL, Bernstein DI, Dubb JW, Faiferman I, Wallin B. 

A placebo

62 ЛЕКАРСТВЕННЫЕ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ

107. Nierop G, Gijzel WP, Bel EH, Zwinderman AH, Dijkman JH.

Auranofin in the treatment of steroid dependent asthma: a dou

108. Richeldi L, Ferrara G, Fabbri L, Lasserson T, Gibson P.

Macrolides for chronic asthma. Cochrane Database Syst Rev
2005(3):CD002997.

109. Kishiyama JL, Valacer D, Cunningham

Richmond GW, Abramson S, et al. A multicenter, randomized,
double

110. Salmun LM, Barlan I, Wolf HM, Eibl M, Twarog FJ, Geha RS, 

et al. Effect of intravenous immunoglobulin on steroid consump

111. Jakobsson T, Croner S, Kjellman NI, Pettersson A, Vassella C,

Bjorksten B. Slight steroid

112. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for

asthma. Cochrane Database Syst Rev 2003(4):CD001186.

113. Bousquet J, Lockey R, Malling HJ, Alvarez

Canonica GW, Chapman MD, et al. Allergen immunotherapy: ther

114. Harrison BD, Stokes TC, Hart GJ, Vaughan DA, Ali NJ, 

Robinson AA. Need for intravenous hydrocortisone in addition to
oral prednisolone in patients admitted to hospital with severe
asthma without ventilatory failure. Lancet 1986;1(8474):181

115. Rowe BH, Edmonds ML, Spooner CH, Diner B, Camargo CA, Jr.

Corticosteroid therapy for acute asthma. Respir Med
2004;98(4):275

116. O’Driscoll BR, Kalra S, Wilson M, Pickering CA, Carroll KB,

Woodcock AA. Double

117. Rodrigo G, Rodrigo C, Burschtin O. A meta

effects of ipratropium bromide in adults with acute asthma. Am J
Med 1999;107(4):363

118. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of

long term treatment with oxitropium bromide on airway secretion
in chronic bronchitis and diffuse panbronchiolitis. Thorax
1994;49(6):545

119. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J

Med 1996;334(21):1380

120. Hondras MA, Linde K, Jones AP. Manual therapy for asthma.

Cochrane Database Syst Rev 2005(2):CD001002.

121. Balon JW, Mior SA. Chiropractic care in asthma and allergy. Ann

Allergy Asthma Immunol 2004;93 (2 Suppl 1):S55

122. Slader CA, Reddel HK, Spencer LM, Belousova EG, Armour CL,

Bosnic

123. Bisgaard H. Delivery of inhaled medication to children. J Asthma

1997;34(6):443

124. Pedersen S. Inhalers and nebulizers: which to choose and why.

Respir Med 1996;90(2):69

125. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, 

Rau JL, et al. Device selection and outcomes of aerosol therapy:
Evidence

126. Zar HJ, Weinberg EG, Binns HJ, Gallie F, Mann MD. Lung depo

sition of aerosol—a comparison of different spacers. Arch Dis
Child 2000;82(6):495

127. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) ver

sus nebulisers for beta

128. Shapiro G, Bronsky EA, LaForce CF, Mendelson L, Pearlman D,

Schwartz RH, et al. Dose

129. Agertoft L, Pedersen S. A randomized, double

tion study to compare the minimal effective dose of budesonide
Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin
Immunol 1997;99(6 Pt 1):773

130. Pedersen S, O’Byrne P. A comparison of the efficacy and safety

of inhaled corticosteroids in asthma. Allergy 1997;52(39):1

131. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW.

Inhaled beclomethasone versus placebo for chronic asthma.
Cochrane Database Syst Rev 2005(1):CD002738.

132. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, 

Ohlsson SV, et al. Early intervention with budesonide in mild per

133. Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B,

Cates C. Inhaled fluticasone at different doses for chronic asth

134. Powell H, Gibson PG. High dose versus low dose inhaled corti

costeroid as initial starting dose for asthma in adults and chil

135. The Childhood Asthma Managment Program Research Group.

Long term effects of budesonide or nedocromil in children with
asthma. N Engl J Med 2000;343(15):1054

136. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on

symptoms, lung function, and cold air and methacholine respon

137. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of

preschool children with asthma symptoms to fluticasone 
propionate. J Allergy Clin Immunol 2001;108(4):540

138. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ,

Szefler SJ, et al. Long

139. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F.

Intermittent inhaled corticosteroids in infants with episodic
wheezing. N Engl J Med 2006;354(19):1998

140. Pedersen S. Do inhaled corticosteroids inhibit growth in chil

dren? Am J Respir Crit Care Med 2001;164(4):521

141. Agertoft L, Pedersen S. Effect of long

inhaled budesonide on adult height in children with asthma. 
N Engl J Med 2000;343(15):1064

142. Sharek PJ, Bergman DA. Beclomethasone for asthma in chil

dren: effects on linear growth. Cochrane Database Syst Rev
2000;2.

143. Agertoft L, Pedersen S. Bone mineral density in children with

asthma receiving long

144. Hopp RJ, Degan JA, Biven RE, Kinberg K, Gallagher GC.

Longitudinal assessment of bone mineral density in children with
chronic asthma. Ann Allergy Asthma Immunol 1995;75(2):143

145. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and

the risk of fractures in children and adolescents. Pediatrics
2004;114(2):469

ЛЕКАРСТВЕННЫЕ СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ  63